Abbott Laboratories $ABT Stock: Intech Investment Management LLC Trims Holdings

Intech Investment Management LLC decreased its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 16.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 224,681 shares of the healthcare product maker’s stock after selling 45,821 shares during the period. Intech Investment Management LLC’s holdings in Abbott Laboratories were worth $22,205,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Farther Finance Advisors LLC increased its position in shares of Abbott Laboratories by 14.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 84,377 shares of the healthcare product maker’s stock worth $8,339,000 after purchasing an additional 10,431 shares during the last quarter. Juncture Wealth Strategies LLC bought a new stake in shares of Abbott Laboratories during the 3rd quarter worth approximately $658,000. Aureus Asset Management LLC boosted its holdings in shares of Abbott Laboratories by 25.0% in the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock valued at $34,078,000 after buying an additional 66,422 shares during the last quarter. Thompson Investment Management Inc. boosted its holdings in shares of Abbott Laboratories by 786.0% in the 2nd quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker’s stock valued at $1,276,000 after buying an additional 12,474 shares during the last quarter. Finally, Clear Harbor Asset Management LLC acquired a new stake in shares of Abbott Laboratories in the 2nd quarter valued at approximately $4,889,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ABT. Royal Bank Of Canada decreased their target price on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Thursday, October 22nd. Barclays began coverage on shares of Abbott Laboratories in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price target on the stock. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a research note on Thursday, August 13th. Citigroup decreased their price objective on shares of Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating for the company in a research report on Thursday, October 22nd. Finally, Weiss Ratings upgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $118.32.

Read Our Latest Report on Abbott Laboratories

Insider Buying and Selling

In other Abbott Laboratories news, EVP Mary Moreland sold 3,500 shares of Abbott Laboratories stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $116.00, for a total transaction of $406,000.00. Following the completion of the transaction, the executive vice president directly owned 100,791 shares of the company’s stock, valued at $11,691,756. The trade was a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Price Performance

NYSE:ABT opened at $108.59 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.45 and a debt-to-equity ratio of 0.57. The stock’s 50 day moving average price is $103.93 and its two-hundred day moving average price is $101.74. The firm has a market capitalization of $188.08 billion, a price-to-earnings ratio of 40.52, a P/E/G ratio of 1.90 and a beta of 0.54. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.42. The company had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The business’s revenue was up 14.5% on a year-over-year basis. During the same period last year, the firm posted $1.30 earnings per share. On average, analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 94.03%.

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Featured Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.